GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR

GSA Capital Partners LLP purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 215,675 shares of the biotechnology company’s stock, valued at approximately $1,555,000. GSA Capital Partners LLP owned about 0.47% of Capricor Therapeutics at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC bought a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at about $28,000. Parkside Financial Bank & Trust acquired a new position in Capricor Therapeutics during the third quarter worth approximately $36,000. Tower Research Capital LLC TRC raised its stake in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares during the period. Envestnet Asset Management Inc. acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at approximately $99,000. Finally, Sheets Smith Investment Management bought a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $107,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CAPR has been the topic of a number of research analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Capricor Therapeutics in a research note on Wednesday, January 14th. iA Financial set a $48.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. B. Riley Financial reaffirmed a “buy” rating and set a $50.00 target price (up previously from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. Finally, Oppenheimer raised their price objective on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.82.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $23.03 on Wednesday. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The stock has a market capitalization of $1.05 billion, a P/E ratio of -12.79 and a beta of 0.38. The stock’s fifty day moving average is $25.49 and its 200 day moving average is $13.98.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.